Oncoceutics to Present Additional Data at ASCO Showing Clinical Benefit from ONC201 for Cancer Patients
Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the virtual 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) from Friday, May 29th to Tuesday, June 2nd that highlight the clinical safety and efficacy of ONC201 across a number of clinical trials, age groups and tumor types, including H3 K27M-mutant diffuse midline glioma. Additionally, a dedicated abstract will present the rationale and design of the first-in-human clinical trial for ONC206, the company’s second molecule of its portfolio of imipridones to enter clinical development.
“The data presented at ASCO 2020 highlights the potential of ONC201 to address the substantial need for patients with H3 K27M-mutant glioma,” said Lee Schalop, MD, Chief Executive Officer of Oncoceutics. “We are committed to build on this promising data and to help ensure that brain cancer patients benefit from the development of ONC201 and other new therapeutic options.”
“We are encouraged by the clinical efficacy of ONC201 in a molecular subset of high-grade gliomas that has continued to be robust as the results grow and mature,” added Joshua Allen, PhD, Chief Scientific Officer of Oncoceutics. “We are further looking forward to the first clinical trial with ONC206 that offers new ways to address additional forms of cancers that lack effective treatments.”
A team of Oncoceutics team members will be available for questions around the conference. If you have any questions, please contact us at [email protected].
A full list of ONC201 and ONC206-related abstracts can be found below:
2563. Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma. https://meetinglibrary.asco.org/record/189924/abstract
3615. Single agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. https://meetinglibrary.asco.org/record/188339/abstract
3617. Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma. https://meetinglibrary.asco.org/record/188239/abstract
3619. ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG. https://meetinglibrary.asco.org/record/187807/abstract
TPS2576. A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. https://meetinglibrary.asco.org/record/191691/abstract
E16703. Phase II study of ONC201 in pheochromocytoma-paragangliomas (PC-PG), medullary thyroid carcinoma (MTC), and other neuroendocrine tumors.
E14552. Epidermal growth factor receptor expression as a molecular determinant of glioblastoma response to the dopamine receptor D2 antagonist, ONC201.
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist and ClpP agonist. The company is supported by grants from NCI, FDA, The Musella Foundation, and the National Brain Tumor Society, and a series of private and public partnerships.
Visit Oncoceutics for more information.